Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-05-08
2007-05-08
Oh, Taylor Victor (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S568000, C562S450000
Reexamination Certificate
active
11238502
ABSTRACT:
Selective MMP-13 inhibitors are isophthalic acid derivatives of the formulawherein:R1, R2, and R3independently are hydrogen, halo, hydroxy, C1–C6alkyl, C1–C6alkoxy, C2–C6alkenyl, C2–C6alkynyl, NO2, NR4R5, CN, or CF3;E is independently O or S;A and B independently are OR4or NR4R5;each R4and R5independently are H, C1–C6alkyl, C2–C6alkenyl, C2–C6alkynyl, (CH2)naryl, (CH2)ncycloalkyl, (CH2)nheteroaryl, or R4and R5when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;n is 0 to 6;or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases in a mammal that are mediated by MMP enzymes.
REFERENCES:
patent: 5130317 (1992-07-01), Baader et al.
patent: 5260323 (1993-11-01), Baader et al.
patent: 5519038 (1996-05-01), Baader et al.
patent: 5948780 (1999-09-01), Peterson, Jr. et al.
patent: 6008243 (1999-12-01), Bender et al.
patent: 2002/0156061 (2002-10-01), Barvian et al.
patent: 2003/0229103 (2003-12-01), Weithmann et al.
patent: 2082076 (1993-05-01), None
patent: 0 418 797 (1991-03-01), None
patent: 0 463 592 (1992-01-01), None
patent: 0 935 963 (1999-08-01), None
patent: 1 138 680 (2001-10-01), None
patent: 5-193260 (1993-08-01), None
patent: WO 99/05148 (1999-02-01), None
patent: WO 00/09485 (2000-02-01), None
patent: WO 01/05389 (2001-01-01), None
patent: WO 01/12611 (2001-02-01), None
patent: WO 01/63244 (2001-08-01), None
patent: WO 02/34726 (2002-05-01), None
patent: WO 02/34753 (2002-05-01), None
patent: WO 02/064568 (2002-08-01), None
patent: WO 02/064571 (2002-08-01), None
patent: WO 03/049738 (2003-06-01), None
Tong et al , Synthesis of a platelet antiaggregant-picotamide and its analogs, 1992, Zhong Yaoke Daxue Xuebao, 23(1), 1-4, a copy of abstract p. (1).
Montana and Baxter, “The design of selective non-substrate-based matrix metalloproteinase inhibitors”, Current Opinion in Drug Discovery & Development, 2000, vol. 3, No. 4, pp. 353-361.
Clark et al., “Matrix metalloproteinase inhibitors in the treatment of arthritis”, Current Opinion in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000, vol. 2, No. 1, pp. 16-25.
Chen et al., “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J. Am. Chem. Soc., 2000. vol. 122, No. , pp. 9648-9654.
Boger et al., Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin. alpha. V. beta. 3, Journal of the American Chemical Society 2001; 123:1280-1288.
Silletti et al., “Disruption of matrix metalloproteinase 2 binding to integrin alpha. v. beta. 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo”, Proceeding of the National Academy of Sciences of the United States of America 2001; 98(1)119-124.
Milton et al., “Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2”, Bioorganic & Medicinal Chemistry Letters, Oxford, GB 1998; 8:2623-2628.
Office Action mailed Jun. 16, 2003 in U.S. Appl. No. 10/264,764, Paper No. 6, 19 pages.
Ye et al., “Catalytic Domains of Matrix Metalloproteinases: A Molecular Biology Approach to Drug Discovery”, Curr.Med.Chem., 1996, vol. 3, pp. 407-418.
Lovejoy et al., “Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors”, Nature Structural Biol., 1999, vol. 6, No. 3, pp. 217-221.
Moy et al., “High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor”, J. Mol. Biol., 2000, vol. 302, pp. 671-689.
Mitchell et al., “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., 1996, vol. 97, No. 3, pp. 761-768.
Neuhold et al., “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice”, J. Clin. Invest., 2001, vol. 107, No. 1, pp. 35-44.
Dahlberg et al., Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor that Spares Collagenase I (Matrix Metalloproteinase 1), Arthritis & Rheumatism, 2000, vol. 43, No. 3, pp. 673-682.
Billinghurst et al., “Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleuken-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase”, Arthritis & Rheumatism, 2000, vol. 43, No. 3, pp. 664-672.
Billinghurst et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage”, J. Clin. Invest., 1997, vol. 99, No. 7, pp. 1534-1545.
Hirota et al., “Novel Synthesis of Pyrido[3,4-d]pyrimidines, Pyrido[2,3-d]-pyrimidines, and Quinazolines via Palladium-Catalyzed Oxidative coupling”, Heterocycles, 1994, vol. 37, No. 1, pp. 563-570.
PCT International Search Report, PCT/IB02/00344, date of mailing Oct. 16, 2002.
Zeen et al., “Synthesis of A Platelet Antiaggregant—Picotamide and Its Analogues”, Journal of China Pharmaceutical Industry, vol. 23, No. 1, 1992, pp. 1-4.
Barvian Nicole Chantel
Connor David Thomas
Dyer Richard Dennis
Johnson Adam Richard
Patt William Chester
Ashbrook Charles W.
Crissey Todd M.
Oh Taylor Victor
Purchase, Jr. Claude F.
Warner-Lambert & Company
LandOfFree
Isophthalic acid derivatives as matrix metalloproteinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isophthalic acid derivatives as matrix metalloproteinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isophthalic acid derivatives as matrix metalloproteinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3721812